PARP1 and posterior cortical atrophy: It was suggested that ETS fusion positive PCa patients could benefit from treatment with poly (ADP-ribose) polymerase 1 (PARP1) inhibitors because TMPRSS2:ERG interacts in a DNA-independent manner with PARP-1 and the catalytic subunit of DNA protein kinase (DNA-PKcs).